Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study.

Fabrizio VernieriNicoletta BrunelliMarilena MarcosanoCinzia AuriliaGabriella EgeoCarlo LovatiValentina FavoniArmando PerrottaIlaria MaestriniRenata RaoLuigi d'OnofrioCinzia FinocchiMarco AguggiaFrancesco BonoAngelo RanieriMaria Albanese Vittorio DI PieroSabina CevoliClaudia Altamura Barbanti Pieronull null

Published in: European journal of neurology (2022)

Galcanezumab was effective and well-tolerated in the 1-year term, with most patients presenting MMD ≥50% RR for at least 9 months. Triptan response, lower BMI, and MMD ≥50% RR in the first month emerged as predictive factors for a persistent response.

Keyphrases

end stage renal disease
newly diagnosed
prognostic factors
peritoneal dialysis
body mass index
clinical trial
preterm infants
cross sectional
smoking cessation
weight loss
replacement therapy